PMID- 29155367
OWN - NLM
STAT- MEDLINE
DCOM- 20180816
LR  - 20180816
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Linking)
VI  - 79
IP  - 2
DP  - 2018 Feb
TI  - Predicted indirectly recognizable HLA epitopes are not associated with clinical 
      outcomes after haploidentical hematopoietic stem cell transplantation.
PG  - 117-121
LID - S0198-8859(17)30533-5 [pii]
LID - 10.1016/j.humimm.2017.11.004 [doi]
AB  - Haploidentical stem cell transplantation (haplo-SCT) provides an alternative 
      method to cure patients with malignant and nonmalignant hematologic diseases who 
      lack a human leukocyte antigen (HLA) matched related or unrelated donor. HLA 
      disparity between donor and patient was the main reason causing lots of clinical 
      immune response. The aim of this study was to investigate whether indirect 
      recognition of mismatched HLA could predict the clinical outcomes in haplo-SCT. 
      The probability of indirect recognition was predicted by the Predicted Indirectly 
      ReCognizable HLA Epitopes (PIRCHE) model. 577 patients with acute leukemia or 
      myelodysplastic syndrome receiving haplo-SCT were enrolled in the study. Patients 
      were divided into 4 quartiles according to PIRCHE-Ⅰ or PIRCHE-Ⅱ. Although the 
      cumulative incidences of chronic graft-versus-host disease (GVHD) were 
      significantly different among the 4 PIRCHE-Ⅰgroups, with 20.4% for group 0-6, 
      40.5% for group >6-11, 26.1% for group >11-19 and 23.9% for group >19 (P = .007), 
      PIRCHE-Ⅰ was not significantly associated with chronic GVHD in multivariate 
      models (RR, 0.993; 95% CI, 0.858-1.149; P = .926). And no significant 
      associations were observed between PIRCHE-Ⅰ or PIRCHE-Ⅱ and other clinical 
      outcomes. In summary, PIRCHE did not correlate with clinical outcomes and could 
      not predict haplo-SCT outcomes.
CI  - Copyright (c) 2017. Published by Elsevier Inc.
FAU - Huo, Ming-Rui
AU  - Huo MR
AD  - Peking University People's Hospital & Peking University Institute of Hematology, 
      Beijing, China.
FAU - Li, Dan
AU  - Li D
AD  - Peking University People's Hospital & Peking University Institute of Hematology, 
      Beijing, China.
FAU - Chang, Ying-Jun
AU  - Chang YJ
AD  - Peking University People's Hospital & Peking University Institute of Hematology, 
      Beijing, China.
FAU - Xu, Lan-Ping
AU  - Xu LP
AD  - Peking University People's Hospital & Peking University Institute of Hematology, 
      Beijing, China.
FAU - Zhang, Xiao-Hui
AU  - Zhang XH
AD  - Peking University People's Hospital & Peking University Institute of Hematology, 
      Beijing, China.
FAU - Liu, Kai-Yan
AU  - Liu KY
AD  - Peking University People's Hospital & Peking University Institute of Hematology, 
      Beijing, China.
FAU - Huang, Xiao-Jun
AU  - Huang XJ
AD  - Peking University People's Hospital & Peking University Institute of Hematology, 
      Beijing, China; Beijing Key Laboratory of Hematopoietic Stem Cell 
      Transplantation, Beijing, China; Peking-Tsinghua Center for Life Sciences, 
      Beijing, China. Electronic address: xjhrm@medmail.com.cn.
LA  - eng
PT  - Journal Article
DEP - 20171116
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (HLA Antigens)
RN  - 0 (Immunodominant Epitopes)
RN  - 0 (Isoantigens)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Child
MH  - Child, Preschool
MH  - Chronic Disease
MH  - Computer Simulation
MH  - Female
MH  - Graft vs Host Disease/*immunology
MH  - HLA Antigens/*metabolism
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Immunodominant Epitopes/*metabolism
MH  - Isoantigens/*metabolism
MH  - Leukemia/*therapy
MH  - Male
MH  - Middle Aged
MH  - Myelodysplastic Syndromes/*therapy
MH  - Transplantation, Haploidentical
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - HLA allele
OT  - Haploidentical
OT  - Outcome
OT  - PIRCHE
EDAT- 2017/11/21 06:00
MHDA- 2018/08/17 06:00
CRDT- 2017/11/21 06:00
PHST- 2017/06/22 00:00 [received]
PHST- 2017/11/07 00:00 [revised]
PHST- 2017/11/09 00:00 [accepted]
PHST- 2017/11/21 06:00 [pubmed]
PHST- 2018/08/17 06:00 [medline]
PHST- 2017/11/21 06:00 [entrez]
AID - S0198-8859(17)30533-5 [pii]
AID - 10.1016/j.humimm.2017.11.004 [doi]
PST - ppublish
SO  - Hum Immunol. 2018 Feb;79(2):117-121. doi: 10.1016/j.humimm.2017.11.004. Epub 2017 
      Nov 16.